Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian Multicenter Study.
Frantellizzi V, Costa R, Mascia M, Spanu A, Farcomeni A, Licari M, Cindolo L, Nuvoli S, Pontico M, De Vincentis G. Frantellizzi V, et al. Among authors: licari m. Clin Genitourin Cancer. 2020 Jun;18(3):185-191. doi: 10.1016/j.clgc.2019.10.009. Epub 2019 Oct 16. Clin Genitourin Cancer. 2020. PMID: 32173355
Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with 223Radium-dichloride: a national multicenter study.
Frantellizzi V, Monari F, Mascia M, Costa R, Rubini G, Spanu A, Di Rocco A, Lodi Rizzini E, Cindolo L, Licari M, Lavelli V, Nuvoli S, De Angelis C, Dionisi V, Ferrari C, De Vincentis G. Frantellizzi V, et al. Among authors: licari m. Ann Nucl Med. 2020 Oct;34(10):772-780. doi: 10.1007/s12149-020-01501-7. Epub 2020 Jul 11. Ann Nucl Med. 2020. PMID: 32654030 Free PMC article.
Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study.
Frantellizzi V, Monari F, Mascia M, Costa R, Rubini G, Spanu A, Farcomeni A, Lodi Rizzini E, Cindolo L, Licari M, Lavelli V, Nuvoli S, Ricci M, Dionisi V, Nappi AG, De Vincentis G. Frantellizzi V, et al. Among authors: licari m. Int J Radiat Biol. 2020 Dec;96(12):1608-1613. doi: 10.1080/09553002.2020.1838655. Epub 2020 Nov 3. Int J Radiat Biol. 2020. PMID: 33074066 Clinical Trial.
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M, Rebuzzi SE, Signori A, Frantellizzi V, Murianni V, Lodi Rizzini E, Mascia M, Lavelli V, Donegani MI, Ponzano M, Gaudiano A, Stazza ML, Licari M, Cavallini L, Laghi V, Cindolo L, Maggi M, Sciarra A, Mammucci P, Sambuceti G, Costa RP, Spanu A, Rubini G, Monari F, De Vincentis G, Fornarini G. Bauckneht M, et al. Among authors: licari m. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1063-1074. doi: 10.1007/s00259-021-05550-6. Epub 2021 Sep 6. Eur J Nucl Med Mol Imaging. 2022. PMID: 34486070 Free PMC article.
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Serretta V, Valerio MR, Costa R, Tripoli V, Murabito A, Princiotta A, Scalici Gesolfo C, Borsellino N, Verderame F, Gebbia V, Licari M, Sanfilippo C; members of the GSTU Foundation. Serretta V, et al. Among authors: licari m. Urol Oncol. 2019 Dec;37(12):964-969. doi: 10.1016/j.urolonc.2019.08.009. Epub 2019 Oct 7. Urol Oncol. 2019. PMID: 31601517
72 results